Neogen Corporation's second quarter earnings call, moderated by the head of Investor Relations, provides an overview of non-GAAP financial measures, highlights forward-looking statements, and acknowledges risks, before transitioning to the CEO and new CFO for further discussion.

A company leader discusses Neogen's progress in overcoming challenges, implementing cost-saving measures, and enhancing commercial and operational strategies. Highlights include leadership changes, targeted growth in food and animal safety, and a focus on innovation and efficiency, aiming for a stronger, more disciplined organization poised for future growth.

Neogen reports Q2 revenue growth, emphasizing food safety segment advancements and divestiture impacts. Core growth returns after four quarters, with strong gains in indicator testing and culture media, driven by sample collection and Petrie film. Pathogens lead bacterial growth, while allergens offset natural toxins decline.

Despite ongoing disruptions in food production and plant closures, the company achieved strong Q2 results. Animal safety segment revenues were flat, with growth in biosecurity and genomics, offset by declines in other areas. Regional performances varied, with the EMEA region seeing declines, while others reported growth in specific product categories. The company anticipates a reversal in production animal herd trends next year due to record beef prices, but remains cautious in guidance until more positive signs are evident.

The second quarter saw improved gross margins and adjusted EBITDA margins, attributed to higher volumes and cost reductions. However, inventory write-offs were elevated, seen as a multi-quarter process to return to normal levels. Guidance for the full fiscal year was raised, projecting revenue between $845M and $855M, and adjusted EBITDA of around $175M, reflecting cautious optimism for the second half amid lingering market weakness.

The company is in the process of divesting its global genomics business, prioritizing net proceeds for debt reduction and aiming to simplify and focus operations. With a strengthened leadership team and renewed commitment to innovation and customer partnerships, the organization is poised for enhanced margins and future growth. Employees' dedication and resilience are acknowledged as critical to driving success.

Instructions are given on how to ask questions and manage participation during a phone-based Q&A, emphasizing the use of keypad functions and speaker phone etiquette.

The focus is on assembling a team of experienced leaders in diagnostics and life sciences to drive global business improvements. Key priorities include optimizing growth, mastering fundamentals, and implementing global processes with a robust onboarding plan. The team's expertise in similar industries ensures a smooth transition, with immediate impact anticipated due to their operational acumen.

The dialogue focuses on strategies to improve margins and profitability in sample handling, noting a favorable trend with expected positive outcomes in the year's second half, impacting EBITDA margins.

Discussion on maintaining conservative fiscal guidance despite robust second quarter results, emphasizing predictability, new team integration, and macroeconomic uncertainties. Inquiry into one-time revenue tailwinds and their impact on recurring adjustments for future quarters.

A notable $2 million insecticide tailwind in Q2 was highlighted as a one-time factor in the animal safety segment. Emphasis on commercial excellence, focusing on key products like petrof, grandm pathogens, and allergens, led to very healthy returns. The organization's response to this focus was praised, attributing much of the growth to driving specificity and commercial excellence.

The implementation of a weekly best estimate process, involving sales leaders and supporting functions, has streamlined the organization's focus on enabling the commercial team, leading to more accurate forecasting and improved business expectations.

The dialogue emphasizes a strategic shift towards a customer-centric approach, with the commercial team at the forefront, supported by the rest of the organization. It highlights early successes in this initiative, reflected in Q2 performance. Additionally, confidence in the timely execution of the feature film manufacturing process is expressed, noting successful production testing and initial product validation phases, with a continued focus on talent and resources to meet the November 2027 timeline.

Discussion on the organic growth in culture media products, highlighting volume-driven sales, market leadership, and organic growth from product lines. Emphasis on overcoming supply issues and regaining market position in allergens, with a focus on sustainable growth strategies for the remainder of the year.

Discussion revolves around potential pricing opportunities within film distribution, emphasizing inflationary pricing adjustments tied to contract renewals and new launches. Volume growth is highlighted, with an expectation of market stabilization post a distributor's inventory adjustment in Q1, forecasting stronger performance akin to Q2 for the rest of the year.

Dialogue highlights customer support for Neogen despite supply issues, emphasizing their role as a vital food safety partner. Recovery efforts focus on volume growth over price increases, with global customer commitment noted.

Closing remarks were given, thanking participants and inviting them to continue conversations at an upcoming event. The call was then concluded with a request to disconnect lines.